117 related articles for article (PubMed ID: 25384907)
1. Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.
van der Straten A; Mayo A; Brown ER; Amico KR; Cheng H; Laborde N; Marrazzo J; Torjesen K
AIDS Behav; 2015 May; 19(5):770-83. PubMed ID: 25384907
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
van der Straten A; Stadler J; Luecke E; Laborde N; Hartmann M; Montgomery ET;
J Int AIDS Soc; 2014; 17(3 Suppl 2):19146. PubMed ID: 25224610
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
4. Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence.
Katz AWK; Mensch BS; Woeber K; Musara P; Etima J; van der Straten A
BMC Womens Health; 2019 Jan; 19(1):18. PubMed ID: 30683103
[TBL] [Abstract][Full Text] [Related]
5. Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.
Koester KA; Liu A; Eden C; Amico KR; McMahan V; Goicochea P; Hosek S; Mayer KH; Grant RM
AIDS Care; 2015; 27(10):1199-204. PubMed ID: 26001026
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP".
Mayer KH; Safren SA; Elsesser SA; Psaros C; Tinsley JP; Marzinke M; Clarke W; Hendrix C; Wade Taylor S; Haberer J; Mimiaga MJ
AIDS Behav; 2017 May; 21(5):1350-1360. PubMed ID: 27848089
[TBL] [Abstract][Full Text] [Related]
7. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
Montgomery ET; Mensch B; Musara P; Hartmann M; Woeber K; Etima J; van der Straten A
AIDS Behav; 2017 Feb; 21(2):481-491. PubMed ID: 27858268
[TBL] [Abstract][Full Text] [Related]
8. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.
van der Straten A; Brown ER; Marrazzo JM; Chirenje MZ; Liu K; Gomez K; Marzinke MA; Piper JM; Hendrix CW;
J Int AIDS Soc; 2016; 19(1):20642. PubMed ID: 26850270
[TBL] [Abstract][Full Text] [Related]
9. Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.
Minnis AM; van der Straten A; Salee P; Hendrix CW
AIDS Behav; 2016 Jul; 20(7):1541-8. PubMed ID: 25969178
[TBL] [Abstract][Full Text] [Related]
10. Exploratory survey of Florida pharmacists' experience, knowledge, and perception of HIV pre-exposure prophylaxis.
Shaeer KM; Sherman EM; Shafiq S; Hardigan P
J Am Pharm Assoc (2003); 2014; 54(6):610-7. PubMed ID: 25343624
[TBL] [Abstract][Full Text] [Related]
11. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
Mensch BS; Brown ER; Liu K; Marrazzo J; Chirenje ZM; Gomez K; Piper J; Patterson K; van der Straten A
AIDS Behav; 2016 Nov; 20(11):2654-2661. PubMed ID: 26906023
[TBL] [Abstract][Full Text] [Related]
12. Sharing of Investigational Drug Among Participants in the Voice Trial.
Moodley J; Naidoo S; Moodley J; Ramjee G
AIDS Behav; 2016 Nov; 20(11):2709-2714. PubMed ID: 27146827
[TBL] [Abstract][Full Text] [Related]
13. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa.
van der Straten A; Stadler J; Montgomery E; Hartmann M; Magazi B; Mathebula F; Schwartz K; Laborde N; Soto-Torres L
PLoS One; 2014; 9(2):e89118. PubMed ID: 24586534
[TBL] [Abstract][Full Text] [Related]
14. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.
Luecke EH; Cheng H; Woeber K; Nakyanzi T; Mudekunye-Mahaka IC; van der Straten A;
J Int AIDS Soc; 2016; 19(1):20875. PubMed ID: 27247202
[TBL] [Abstract][Full Text] [Related]
15. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Leethochawalit M; Chiamwongpaet S; Curlin ME; Na-Pompet S; Warapronmongkholkul A; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Choopanya K;
AIDS; 2015 Apr; 29(7):819-24. PubMed ID: 25985403
[TBL] [Abstract][Full Text] [Related]
16. Reaching High-Risk Patients for HIV Preexposure Prophylaxis.
Riddell J; Cohn JA
JAMA; 2016 Jul; 316(2):211-2. PubMed ID: 27404188
[No Abstract] [Full Text] [Related]
17. Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.
Husnik MJ; Brown ER; Marzinke M; Livant E; Palanee-Phillips T; Hendrix CW; Matovu Kiweewa F; Nair G; Soto-Torres LE; Schwartz K; Hillier SL; Baeten JM;
J Acquir Immune Defic Syndr; 2017 Nov; 76(3):330-337. PubMed ID: 28746164
[TBL] [Abstract][Full Text] [Related]
18. Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention.
Drain PK; Bardon AR; Simoni JM; Cressey TR; Anderson P; Sevenler D; Olanrewaju AO; Gandhi M; Celum C
Curr HIV/AIDS Rep; 2020 Oct; 17(5):487-498. PubMed ID: 32627120
[TBL] [Abstract][Full Text] [Related]
19. "It Was Not My Aim to Sleep There": The Impact of Timing and Location of Sex on Adherence to Coitally-Dependent HIV Pre-exposure Prophylaxis.
Scorgie F; Stadler J; Baron D; Ju S; Ikaneng T; Mabude Z; Makgopa S; Malefo MA; Manenzhe KN; Mazibuko T; Ntjana H; Nkala B; Palanee-Phillips T; Gray G; Rees H; Delany-Moretlwe S
AIDS Behav; 2018 Nov; 22(11):3692-3704. PubMed ID: 29909589
[TBL] [Abstract][Full Text] [Related]
20. Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis.
Carroll JJ; Heffron R; Mugo N; Ngure K; Ndase P; Asiimwe S; Celum C; Baeten JM
Sex Transm Dis; 2016 Aug; 43(8):471-5. PubMed ID: 27419812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
